Trials / Completed
CompletedNCT04401800
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
A Phase 2 Study to Investigate the Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) by central site imaging facility per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | Capsules administered orally once daily |
| DRUG | Tislelizumab | 200 mg intravenous (IV) infusion administered on Day 1 of each cycle |
Timeline
- Start date
- 2020-09-04
- Primary completion
- 2022-12-01
- Completion
- 2024-02-18
- First posted
- 2020-05-26
- Last updated
- 2025-03-10
- Results posted
- 2025-03-10
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04401800. Inclusion in this directory is not an endorsement.